Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 19.97M P/E - EPS this Y 58.20% Ern Qtrly Grth -
Income -28.19M Forward P/E -0.74 EPS next Y 5.10% 50D Avg Chg -34.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -19.00%
Dividend N/A Price/Book 0.58 EPS next 5Y - 52W High Chg -52.00%
Recommedations 1.70 Quick Ratio 3.25 Shares Outstanding 30.88M 52W Low Chg 49.00%
Insider Own 18.06% ROA -65.99% Shares Float 23.67M Beta 1.18
Inst Own 36.16% ROE -142.45% Shares Shorted/Prior 402.97K/404.15K Price 0.94
Gross Margin - Profit Margin - Avg. Volume 87,761 Target Price 7.00
Oper. Margin - Earnings Date Nov 12 Volume 163,146 Change -7.84%
About Vincerx Pharma, Inc.

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

Vincerx Pharma, Inc. News
11/12/24 Vincerx Pharma Reports Third Quarter 2024 Financial Results
10/10/24 What Makes Vincerx Pharma (VINC) a New Buy Stock
10/07/24 Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates
08/21/24 Companies Like Vincerx Pharma (NASDAQ:VINC) Could Be Quite Risky
08/08/24 Vincerx Pharma Reports Second Quarter 2024 Financial Results
06/27/24 Vincerx Pharma (VINC) Moves to Buy: Rationale Behind the Upgrade
05/14/24 Vincerx Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
04/25/24 Vincerx Pharma Announces Pricing of Underwritten Public Offering of Common Stock and Warrants
04/25/24 Vincerx Pharma Announces Proposed Underwritten Public Offering of Common Stock and Warrants
04/09/24 Vincerx (VINC) Tumbles on Results From Cancer Therapy Study
04/09/24 Why Is Small-Cap Cancer Focused Vincerx Pharma Stock Plummeting On Tuesday?
04/08/24 Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024
04/01/24 Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/29/24 Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look
03/29/24 Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
03/14/24 12 Most Profitable Biotech Stocks To Invest In
03/05/24 Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
03/05/24 Vincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past week
01/07/24 Vincerx Pharma Announces Compelling Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma
12/19/23 15 Best Falling Stocks To Buy Now
VINC Chatroom

User Image Biotech2424 Posted - 4 hours ago

Liver cancer approval would open up at least 20-30x market for their approved checkpoint inhibitor more than npc’s of $200 mil at Coherus. So that would make stock go up 20-30x.. Barclays’s target of $7 seems decent for existing business Coherus $350 mil projected for 2025. At $1.11 you can’t go wrong these normally trade at 3.5x forward sales that would equate $11.14 per share. So at $1.11 trading at 1/10th. That’s why Tang, Citadel, Rubric, Goldman are all long. Deep value play… Plus the checkpoint inhibitor is safer vascularly than Keytruda. $CHRS $VINC $ADCT $PYXS

User Image CON_or_McGregor Posted - 20 hours ago

$VINC this is what management should do

User Image Biotech2424 Posted - 1 day ago

$CHRS You take their $350 million plus in 2025 and put that into a bigger company it’s like $300 million in profits a year. Like the private equity model fire everyone use existing infrastructure and people on acquisition assets. Then they can squeeze every ounce out of the sales. Plus they can sit on the approved checkpoint inhibitor and get a half dozen label expansions. And blow sales up on that to half billion or more. $PYXS $ADCT $VINC

User Image gotnoidea Posted - 2 days ago

$VINC are there any PR or Updates due before Xmas ?

User Image StockBoy65 Posted - 2 days ago

$VINC looking like it’s heading to be an actual penny stock real soon. A very sad turn of events from being $9 nine months ago.

User Image toolajittooquit Posted - 3 days ago

$VINC the fat lady is getting ready to sing. The party is just about over. https://m.youtube.com/watch?v=2o8vULGTT1U

User Image MarkM Posted - 3 days ago

$VINC would like to see ST poll this ticker: How much longer will you be a bagholder here? a. <1 year b. 1-2 years c. 2-4 years d. >4 years Fairly certain my answer is d. Sequel to "Blood and Money" = "How Stupid Can you Be?"

User Image toolajittooquit Posted - 4 days ago

$VINC slowly will trickle down to below .10. Mgmt is running out of cash. Will see big dilution but it doesn't change the fact that trial results have been not impressive.

User Image Smokeybrewer Posted - 4 days ago

$VINC it’s going to rip tomorrow !!! I can fill it in my bones !!

User Image GPS_OS_21_vs_SOC_5 Posted - 4 days ago

@TomMac64 I posted the Insiders Purchases right after the 10Q came out -- you can see. PS - Never Forget LIDINGOBILL WALKER AKA TELALIE - IS A BALD FACED LIAR - Literally BLATANT LIES, OMISSION AND FABRICATION in EVERY POST. - in this Screen Shot he Lied that 009 ' was Just as Toxic as other so calledCDK9 inhibitors", he posted that lie the day SLS published Safety DATA at ASH, confirming 009 was in FACT SAFE, NO DLT's NONE --- A safe CDK9 Inhibitor is EXTREMELY VALUABLE - $VINC was worth $700M for a hot second based on its CDK9 VIP150, before the tox became evident. ITS WHY BILL LIES ABOUT 009 - ITS WORTH A F TON MORETHAN 90M,

User Image HoHoHoHum Posted - 4 days ago

$VINC $VINC at least until the funding/compliance issues are sorted out there will be downward pressure i think.

User Image FSUFootball Posted - 5 days ago

$VINC Ok,I have all mine. Let it rip!

User Image Restez Posted - 5 days ago

$VINC wake up!

User Image FSUFootball Posted - 5 days ago

$VINC You never know whith penny bio’s.🤷🏻‍♂️

User Image thielindo Posted - 5 days ago

$VINC back again

User Image RaKa82 Posted - 5 days ago

$VINC picked up 20K shares, pure lotto play. I guess I’m

User Image toolajittooquit Posted - 5 days ago

$VINC new all time low today and going lower. Mgmt needs to give out bonuses before the cash is gone.

User Image CON_or_McGregor Posted - 6 days ago

$VINC

User Image GPS_OS_21_vs_SOC_5 Posted - 6 days ago

$SLS $85M - 100% Complete Response in Optimally Dosed ASXL1+ END Stage Dying AML Patients. -- all 009 Needs for FDA Approval is 25%. I am thinking we will Get 4 More 009 Pr's this Quarter ... - DLBCL Genfleet Phase 2 combo Results w Zanubrutinib, - PIVOT NIH Pediatric Results, - ASH P2A Full Publication and Market Reaction, - SLS009 Phase 2B Topline in all ASXL1+ MR Setting, and Possibly PH2B ASH Late Breaker, + GPS Phase 3 REGAL Results, 5 years in the Making. - A Positive P3 Result and $SLS is Instantly worth multiple Billions, it will give Gps the FDA Green Light to Treat upwards of 25,000 AML Remission Patients Each year -a $6B TAM. $KRON $VINC $XBI

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$XBI $SLS SLS009 is already worth More than a Billion - right now - the Market will be Catch ing up to Highbridge. Do some DD on Kura and Sndx Value. SLS009 Phase 2 100% CR Rates are worth a Fu_k ton more than $85M. Dr. Zeidner and Kadia were clear as a bell, all SLS009 needed to beat 25% Response Rates for FDA Approval - Its 100%. " 50% Response Rate in the Optimal dose"... Clinical was even higher in patients .. w ASXL1+ ... Combined w the PreLim data, we can determine Optimal Dosed ASXL1+ patients have a CR Rate of 100% . CR at 100% for End Stage Dying, relapsed and Refractory to Aza VEN, AML Patients. - the market will be correcting the Value Share Price imbalance. -And not 1 Grade 3 or 4 SA, $VINC would be worth 2B by now if VIP150 had these P2A Results. Same thing w $KRON 's CDK9.

User Image GPS_OS_21_vs_SOC_5 Posted - 1 week ago

$SLS $85M MCap ASH publication confirmed 100% Complete Response rates for SLS009 optimally, dosed asxl1+ AML patients, who are relapsed refractory to Aza Ven - look at $SNDX Fda approval for 21% CR in another AML subset, and 25% were Ven naive. SLS009 also has a pristine Safety Profile, the Most Selective and First Ever Safe CDK9 https://ash.confex.com/ash/2024/webprogram/Paper198686.html $kron $VINC - SLS009 100% CR Rates, No DLT's No Serious SA's https://ir.syndax.com/news-releases/news-release-details/syndax-presents-positive-data-pivotal-augment-101-trial

User Image HoHoHoHum Posted - 1 week ago

$VINC interestingly it is holding well on a day like this

User Image FSUFootball Posted - 1 week ago

$VINC I have a very simple theory that (unbelievably works 80% of the time), when none avatar bearish post out weigh bullish avatar post, the ticker is about to pop biggly to the upside.

User Image S_Franconi Posted - 1 week ago

$VINC https://investors.vincerx.com/sec-filings/sec-filing/sc-13g/0001172661-24-005112

User Image HoHoHoHum Posted - 1 week ago

$VINC tax loss selling in full swing

User Image toolajittooquit Posted - 1 week ago

$VINC short to zero.

User Image GSHSRWD Posted - 1 week ago

$VINC emancipated

User Image Biotech2424 Posted - 1 week ago

$VINC Going to zero basically. Load up in CHRS

User Image Wheats03 Posted - 1 week ago

$VINC question? How do you shake down a deal ? Wait

User Image Wheats03 Posted - 1 week ago

$VINC absolute total fuck me....unless you were on the inside like the dude who took down 5+ million shares in his Grand Canyon account. FUCK I've been suckered again ... maybe see you at ¢0.15 .....my last comment. Both of the principal's are being run by bigger monies, because they both don't know how big pharma works.....or there's a deal breaker with Bayer. Which was written a long time ago.

Analyst Ratings
Cantor Fitzgerald Overweight Apr 9, 24
Cantor Fitzgerald Overweight Apr 1, 24
Cantor Fitzgerald Overweight Sep 7, 23
Chardan Capital Buy Nov 17, 22
SVB Leerink Outperform Aug 12, 22
Cantor Fitzgerald Overweight Jun 8, 22
B. Riley Securities Buy Jun 7, 22
Chardan Capital Buy Jun 7, 22
SVB Leerink Outperform Jun 7, 22
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Hamdy Ahmed MD See Remarks See Remarks Aug 09 Buy 0.95 22,300 21,185 96,060 08/10/23
THOMAS TOM C See Remarks See Remarks Aug 10 Buy 0.95 5,000 4,750 219,935 08/10/23
Izumi Raquel E. See Remarks See Remarks Aug 09 Buy 0.92 16,476 15,158 85,214 08/10/23
Izumi Raquel E. See Remarks See Remarks Dec 14 Buy 0.8848 28,738 25,427 68,738 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Dec 14 Buy 0.8656 35,280 30,538 73,760 12/14/22
THOMAS TOM C See Remarks See Remarks Dec 14 Buy 0.83 7,000 5,810 10,000 12/14/22
Hamdy Ahmed MD Chief Executive Offi.. Chief Executive Officer Jun 23 Buy 1.4106 24,200 34,137 38,480 06/27/22
Bushnell Laura I. Director Director Jun 09 Buy 1.9083 15,000 28,624 19,202 06/13/22